Matthen Mathew

521 total citations
13 papers, 321 citations indexed

About

Matthen Mathew is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Matthen Mathew has authored 13 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Immunology. Recurrent topics in Matthen Mathew's work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Matthen Mathew is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Matthen Mathew collaborates with scholars based in United States, Canada and Australia. Matthen Mathew's co-authors include Naiyer A. Rizvi, Catherine A. Shu, Thomas Enzler, Fatemeh Momen‐Heravi, Romil Patel, Yu Wang, Angela J. Yoon, Alison M. Taylor, Xun Wu and Yi‐Shing Lisa Cheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Matthen Mathew

12 papers receiving 319 citations

Peers

Countries citing papers authored by Matthen Mathew

Since Specialization

Citations

This map shows the geographic impact of Matthen Mathew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthen Mathew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthen Mathew more than expected).

Fields of papers citing papers by Matthen Mathew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthen Mathew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthen Mathew. The network helps show where Matthen Mathew may publish in the future.

Co-authorship network of co-authors of Matthen Mathew

This figure shows the co-authorship network connecting the top 25 collaborators of Matthen Mathew. A scholar is included among the top collaborators of Matthen Mathew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthen Mathew. Matthen Mathew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Title	Journal	Authors	Indexed citations
1	INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors	Cancer Immunology Immunotherapy	John Hilton, Patrick A. Ott et al.	10
2	760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors	SHILAP Revista de lepidopterología	Minh D. To, Victoria Atkinson et al.	1
3	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors	Cell Reports Medicine	Shoiab Bukhari, Brian S. Henick et al.	41
4	Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion	Journal of Experimental & Clinical Cancer Research	Xun Wu, Yi‐Shing Lisa Cheng et al.	48
5	Characteristics and outcomes of lung cancer in solid organ transplant recipients	Lung Cancer	John Spivack, Anjali Saqi et al.	7
6	1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)	Annals of Oncology	C. Le Tourneau, Danny Rischin et al.	3
7	ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).	Journal of Clinical Oncology	Matthew T. Campbell, Tian Zhang et al.	3
8	Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).	Journal of Clinical Oncology	Eric Angevin, Stefanie L. Groenland et al.	13
9	Extracellular Vesicles as Biomarkers in Cancer Immunotherapy	Cancers	Matthen Mathew, Romil Patel et al.	79
10	Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)	Annals of Oncology	Danny Rischin, Stefanie L. Groenland et al.	15
11	Combining chemotherapy with PD-1 blockade in NSCLC	Pharmacology & Therapeutics	Matthen Mathew, Thomas Enzler et al.	100
12	Bone marrow aspirate quality assessment.	Journal of Clinical Oncology	Rachael A. Safyan, Matthen Mathew et al.	1
13	Donor-specific suppressor cells and donor-specific loss of cell-mediated lympholysis in renal allograft recipients: a comparative study.	PubMed	Matthen Mathew et al.	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact